2006
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.
Longo D, Glatstein E, Duffey P, Young R, Fiem S, Jaffe E, Camphausen K, Wilson W, DeVita V. A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. Blood 2006, 108: 98. DOI: 10.1182/blood.v108.11.98.98.Peer-Reviewed Original ResearchStage IA diseaseDisease-free survivalComplete responseModality therapyHodgkin's diseaseRadiation therapyMOPP chemotherapyFirst remissionIA diseaseOverall survivalSecond cancersSignificant treatment toxicityStage Hodgkin's diseaseCombined modality therapyRadiation-treated patientsIIIA Hodgkin's diseaseAdministration of radiationInitial remissionProspective trialTreatment toxicityCombination chemotherapyIA patientsLate effectsPatientsMOPP
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma